Description: Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Home Page: www.hansabiopharma.com
PO Box 785
Lund,
220 07
Sweden
Phone:
46 46 16 56 70
Officers
| Name | Title |
|---|---|
| Mr. Søren Tulstrup M.Sc | Pres & CEO |
| Mr. Donato Spota | CFO & Sr. VP |
| Dr. Christian Kjellman | Sr. VP, Chief Scientific Officer & COO |
| Ms. Eva-Maria Joed | VP of Fin. & Admin. |
| Mr. Klaus Sindahl | Head of Investor Relations |
| Ms. Katja Margell | Head of Corp. Communications |
| Ms. Anne Säfström Lanner | Sr. VP & Chief HR Officer |
| Mr. Emanuel Björne | VP & Head of Bus. Devel. |
| Dr. Lena Winstedt | Head of Science |
| Mr. Henk J. Doude van Troostwijk | Sr. VP & Chief Commercial Officer |
Exchange: F
Country: DE
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.4435 |
| Price-to-Sales TTM: | 18.4076 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 145 |